Page last updated: 2024-11-04

beta-alanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID239
CHEMBL ID297569
CHEBI ID16958
MeSH IDM0023212

Synonyms (123)

Synonym
aminopropionic acid
propanoic acid, amino-
gtpl2365
.beta.-aminopropionic acid
nsc7603 ,
abufene
alanine, beta
propanoic acid, 3-amino-
3-aminopropanoic acid
.beta.-alanine
nsc-7603
beta-aminopropionic acid
h-beta-ala-oh
omega-aminopropionic acid
CHEBI:16958 ,
h2nch2ch2cooh
tocris-0206
NCGC00024495-01
D07561
abufene (tn)
OPREA1_583450
PDSP2_000143
inchi=1/c3h7no2/c4-2-1-3(5)6/h1-2,4h2,(h,5,6
beta-alanine (6ci,8ci,9ci)
beta-ala
ai3-18470
beta-aminopropionsaeure
fema no. 3252
alanine, beta-
2-carboxyethylamine
3-aminopropionsaeure
STK301638
107-95-9
3-aminopropanoate
B-ALANINE ,
beta-alanine ,
C00099
3-aminopropionic acid
beta alanine
beta-alanine, bioreagent, suitable for cell culture, suitable for insect cell culture
beta-alanine, >=98%, fg
DB03107
beta-alanine, 99%
NCGC00024495-02
nsc 7603
einecs 203-536-5
PDSP1_000144
7CA041EF-5103-439A-9D84-1761529BA8DA
A0180
3-amino-propionic acid
CHEMBL297569 ,
BMSE000159
alanine-beta
3-aminopropanoic acidbeta-alanine
bdbm50000102
AKOS000119659
ec 203-536-5
unii-11p2jde17b
11p2jde17b ,
beta-alaine
BMSE000967
BMSE001019
a-ala
BP-10083
FT-0622549
AM20080020
beta alanine [usp-rs]
beta-alanine [vandf]
alanine, .beta.-
pamidronate disodium pentahydrate impurity a [ep impurity]
beta-alanine [who-dd]
beta-alanine [inci]
.beta.-alanine [fhfi]
.beta.-alanine [mi]
S5526
3-aminopropionic acid-15n
beta-alanin
beta- alanine
beta--alanine
Q-200704
87867-95-6
beta-alanine #
.omega.-aminopropionic acid
?-alanine
beta-alanine;
b-alanine-2,2,3,3-d4
DTXSID0030823
mfcd00008200
Z57127544
F2191-0213
SR-01000597690-1
sr-01000597690
beta-alanine, bioultra, >=99.0% (nt)
beta-alanine, bioxtra, >=99.0% (nt)
beta-alanine, analytical standard
beta-alanine, united states pharmacopeia (usp) reference standard
beta alanine, pharmaceutical secondary standard; certified reference material
beta alanine; pamidronate disodium pentahydrate imp. a (ep); pamidronate imp. a (ep); calcium pantothenate impurity a; pamidronate disodium pentahydrate impurity a; pamidronate impurity a
3-aminopropanoic acid (beta-alanine)
b-ala
3-aminopropionate
beta-aminopropanoate
b-aminopropionic acid
b-aminopropionate
beta-aminopropionate
3-amino-propanoate
b-aminopropanoate
3-amino-propanoic acid
b-aminopropanoic acid
omega-aminopropionate
beta-aminopropanoic acid
HY-N0230
CS-W020126
FT-0773034
Q310919
beta-alanine-13c3-15n
h-|a-ala-oh
BBL037332
STR03358
25513-34-2
EN300-18046
F86478
beta -alanine

Research Excerpts

Overview

Beta-alanine (BA) is a non-essential amino acid that can be synthesized in the liver and obtained from diet, particularly from white and red meat. It is among the most used sports supplements for improving athletic performance.

ExcerptReferenceRelevance
"Beta-alanine is a limiting precursor of carnosine and is among the most used sports supplements for improving athletic performance."( Carnosine and Beta-Alanine Supplementation in Human Medicine: Narrative Review and Critical Assessment.
Bastlova, P; Cesak, O; Student, V; Vidlar, A; Vostalova, J, 2023
)
1.99
"Beta-alanine (BA) is a popular ergogenic supplement because it can induce muscle carnosine loading. "( Meal and beta-alanine coingestion enhances muscle carnosine loading.
Achten, E; Bex, T; Blancquaert, L; Calders, P; Derave, W; Everaert, I; Stegen, S; Taes, Y, 2013
)
2.25
"Beta-alanine (BA) is a non-essential amino acid that can be synthesized in the liver and obtained from diet, particularly from white and red meat. "( Effects of beta-alanine supplementation on performance and muscle fatigue in athletes and non-athletes of different sports: a systematic review.
Berti Zanella, P; Donner Alves, F; Guerini de Souza, C, 2017
)
2.29
"Beta-alanine is an intermediate in the reductive degradation of uracil. "( Degradation of pyrimidines in Saccharomyces kluyveri: transamination of beta-alanine.
Andersen, G; Dobritzsch, D; Piskur, J; Schnackerz, KD, 2008
)
2.02
"Beta-alanine (β-ALA) is a non-essential amino acid."( Effects of beta-alanine on muscle carnosine and exercise performance: a review of the current literature.
Cooke, M; Culbertson, JY; Greenwood, M; Kreider, RB, 2010
)
1.47
"beta-Alanine is a central-nervous-system depressant."( Hyper-beta-alaninemia associated with beta-aminoaciduria and gamma-aminobutyricaciduria, somnolence and seizures.
Davies, E; Pueschel, S; Scriver, CR, 1966
)
1.45
"beta-Alanine is a relatively potent inhibitor of GAT-3 GABA transport, with a K(i) value of 34 microM."( Stable expression of a neuronal gamma-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence.
Amara, SG; Clark, JA, 1994
)
1.01

Effects

Beta-alanine has become a dietary supplement widely used by athletes due to its ergogenic effect. beta-Alanine has 5 recognized receptor sites: glycine co-agonist site on the NMDA complex, glycine receptor site (strychnine sensitive), GABA-A receptor; GABA-C receptor; and blockade of GAT protein-mediated glial GABA uptake.

ExcerptReferenceRelevance
"Beta-alanine has become a dietary supplement widely used by athletes due to its ergogenic effect. "( Beta-alanine fails to improve on 5000 m running time despite increasing PAT1 expression in long-distance runners.
Brandao, CF; Ferreira, FC; Franco, GS; Nonino, CB; Noronha, NY; Oliveira, BA; Papoti, M; Pinto, AP, 2021
)
3.51
"beta-Alanine has 5 recognized receptor sites: glycine co-agonist site on the NMDA complex (strychnine-insensitive); glycine receptor site (strychnine sensitive); GABA-A receptor; GABA-C receptor; and blockade of GAT protein-mediated glial GABA uptake."( Beta-alanine as a small molecule neurotransmitter.
Barnes, S; Stevens, K; Tiedje, KE; Weaver, DF, 2010
)
2.52

Actions

beta-Alanine can activate the glycine receptor, a major inhibitory receptor in the mammalian central nervous system. The beta-alanine increase in [3H]flunitrazepam binding was completely inhibited by 10 microM strychnine.

ExcerptReferenceRelevance
"beta-Alanine can activate the glycine receptor, a major inhibitory receptor in the mammalian central nervous system; the 2-methoxy-5-nitrophenyl derivative of beta-alanine combined with a laser-pulse photolysis method makes it possible to investigate the chemical kinetic mechanism of the receptor in the 3-microseconds time domain."( Synthesis and characterization of a caged receptor ligand suitable for chemical kinetic investigations of the glycine receptor in the 3-microseconds time domain.
Carpenter, BK; Hess, GP; Niu, L; Ramesh, D; Wieboldt, R, 1996
)
1.02
"The beta-alanine increase in [3H]flunitrazepam binding was completely inhibited by 10 microM strychnine, whereas the GABA increase required 0.1 mM strychnine to be fully suppressed."( Beta-alanine potentiation of [3H]flunitrazepam binding to rat spinal cord homogenates.
Córdoba, C; Fernández, I; Orensanz, LM, 1990
)
2.2
"beta-Alanine was shown to inhibit taurine uptake in neurons and astrocytes, also in a competitive manner, with Ki values of 72 microM in neurons and 71 microM in astrocytes."( Mutual inhibition kinetic analysis of gamma-aminobutyric acid, taurine, and beta-alanine high-affinity transport into neurons and astrocytes: evidence for similarity between the taurine and beta-alanine carriers in both cell types.
Allen, IC; Griffiths, R; Larsson, OM; Schousboe, A, 1986
)
1.22

Treatment

beta-alanine pretreated rats, the increase in the bile flow in the first hr was more rapid compared to control rats. Oral treatment had fewer obvious side effects than injections, but all treated rats had body weights less than age-matched controls.

ExcerptReferenceRelevance
"This beta-alanine treatment to dams increased beta-alanine concentration, but did not decrease taurine concentrations in milk, and serum taurine concentration in the pups receiving this milk was elevated."( Effect of taurine in rat milk on the growth of offspring.
Hu, JM; Nishihara, M; Rho, JY; Suzuki, M; Takahashi, M, 2000
)
0.76
"In beta-alanine pretreated rats, the increase in the bile flow in the first hr was more rapid compared to control rats, and the bile flow rate reached a peak earlier."( Ursodeoxycholate-induced choleresis in taurine-deprived and taurine-supplemented rats.
Kanai, S; Kitani, K, 1985
)
0.78
"Oral treatment with beta-alanine had fewer obvious side effects than injections, but all treated rats had body weights less than age-matched controls."( Effects of beta-alanine treatment on the taurine and DNA content of the rat heart and retina.
De Marte, L; Lake, N, 1988
)
0.98

Toxicity

ExcerptReferenceRelevance
" As for the safety, an increase in the platelet count and slight evaluation of GOT and GPT were seen in 1 case as abnormal changes in the laboratory findings, although no side-effect was observed."( [Studies on efficacy and safety of panipenem/betamipron against infections in pediatrics and on its movement to cerebrospinal fluid including cases of penicillin-resistant Streptococcus pneumoniae meningitis].
Haruta, T; Kobayashi, Y; Kuroki, S; Naramura, M; Nikami, H; Nishio, T; Ohkura, K, 1992
)
0.28
" In terms of survival time in relation to the cumulative dose and molecular weight, FBAL was more toxic than FA."( Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine.
Kuroiwa, T; Matsuo, T; Okeda, R; Shibutani, M; Shimokawa, R; Tajima, T, 1990
)
0.47
" We have investigated the toxicity of these amino acids on cultured mouse cortical neurons in the presence of physiological concentrations of bicarbonate (a required toxic cofactor for BMAA neurotoxicity)."( Neurotoxicity of beta-N-methylamino-L-alanine (BMAA) and beta-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons.
Choi, DW; Koh, JY; Weiss, JH, 1989
)
0.28
" Uracil plus tegafur was shown to be less toxic than the drug alone in all the species, and uracil was found to decrease the toxicity of tegafur."( Effect of coadministration of uracil on the toxicity of tegafur.
Haruno, A; Kunimune, Y; Morita, K; Unemi, N; Yamamoto, J; Yamashita, K; Yoshimura, Y, 1984
)
0.27
" Toxic effects of the peptide were seen at 200 microg/ml A beta using a mitochondrial dehydrogenase activity (MTT) reduction assay, lactate dehydrogenase release and glucose consumption."( Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine.
Abbott, JN; Himsworth, DT; Hipkiss, AR; Preston, JE; Romero, IA, 1998
)
0.51
" The Cd-chelate complexes proved highly more toxic compared to Mn-chelate complexes or uncomplexed chelates exhibiting LC(50) values of 130-200 microg/L."( The acute toxicity of gluconic acid, beta-alaninediacetic acid, diethylenetriaminepentakismethylenephosphonic acid, and nitrilotriacetic acid determined by Daphnia magna, Raphidocelis subcapitata, and Photobacterium phosphoreum.
Dhondup, P; Pirkanniemi, K; Sillanpää, M, 2003
)
0.59
" Previous workers showed that the reactive-sulphur-containing fragment released from S -(1,1,2,2-tetrafluoroethyl)-L-cysteine and S -(1,2-dichlorovinyl)-L-cysteine is toxic by acting as a thioacylating agent - particularly of lysine residues in nearby proteins."( L-alanine-glyoxylate aminotransferase II of rat kidney and liver mitochondria possesses cysteine S-conjugate beta-lyase activity: a contributing factor to the nephrotoxicity/hepatotoxicity of halogenated alkenes?
Cooper, AJ; Jeitner, TM; Krasnikov, BF; Okuno, E, 2003
)
0.32
" Neurotoxic signs such as hyperesthesia and/or excitement, as well as convulsions, were observed in both FBAL x HCl and FA x Na groups; these toxic signs were also found in the UFT group."( Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs.
Ariyoshi, T; Yada, H; Yamashita, K, 2004
)
0.6
" More active, stable and less toxic CPPs can be designed by optimizing the position and number of R, D-R, X and B residues."( Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity.
Hassinger, JN; Iversen, PL; Lovejoy, CE; Moulton, HM; Nelson, MH; Wu, RP; Youngblood, DS, 2007
)
0.34
" In addition, these beta-peptides were not toxic to HeLa and COS-1 cell lines as observed by MTT cytotoxicity assay."( The proteolytic stability and cytotoxicity studies of L-aspartic acid and L-diaminopropionic acid derived beta-peptides and a mixed alpha/beta-peptide.
Ahmed, S; Kaur, K, 2009
)
0.35
" In general, the most toxic compound was 5-FU."( Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites.
Blaha, L; Dott, W; Kovalova, L; Zounkova, R, 2010
)
0.36
" Dabigatran at a dose of 110mg twice daily was safe for AF ablation in patients with a relatively low risk of thromboemboli, suggesting that it may become an alternative to warfarin in those patients."( Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Fuke, E; Hayano, M; Kaseno, K; Kumagai, K; Miki, Y; Naito, S; Nakamura, K; Nishiuchi, S; Oshima, S; Sakamoto, T; Sasaki, T; Tada, H; Tsukada, N; Yamashita, E, 2012
)
0.38
"Dabigatran, an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation."( Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S, 2012
)
0.38
" All the adverse events were recorded."( [The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection].
, 2012
)
0.38
"Intravenous panipenem-betamipron is effective in treating moderate to severe pulmonary infection with low adverse events rate."( [The clinical efficacy and safety of panipenem-betamipron in treatment of moderate to severe pulmonary infection].
, 2012
)
0.38
" We analyzed data from this trial to quantify upper gastrointestinal nonbleeding adverse events (NB-UGI AEs)."( Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S, 2013
)
0.39
" Adverse effects reported in association with preworkout supplements include gastrointestinal symptoms, cardiac arrhythmia, blood pressure increases, and potential effects on lipids and blood glucose."( Efficacy and safety of ingredients found in preworkout supplements.
Ambrose, PJ; Eudy, AE; Gordon, LL; Hockaday, BC; Lee, DA; Lee, V; Luu, D; Martinez, CA, 2013
)
0.39
"Peri-procedural anticoagulation therapy with dabigatran for RFCA of AF was equally safe and effective compared with warfarin and heparin bridging."( Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.
Fujiwara, R; Fukuzawa, K; Hirata, K; Imamura, K; Itoh, M; Kiuchi, K; Matsumoto, A; Nakanishi, T; Suzuki, A; Takami, K; Takami, M; Takei, A; Yamashita, S; Yoshida, A, 2013
)
0.39
"We described the changes in the attitudes of attending physicians toward dabigatran prescription after the blue letter in a specialized hospital for cardiovascular care in Japan, which, we believe, involve useful information for safe use of dabigatran in a real-world clinical setting."( "Blue letter effects": Changes in physicians' attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan.
Aizawa, T; Kano, H; Kirigaya, H; Koike, A; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Takai, H; Tanabe, H; Uejima, T; Yajima, J; Yamashita, T, 2013
)
0.39
" Orally administered dabigatran after discharge from hospital appears safe for venous thromboembolism prophylaxis after RALP."( Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation.
Joutsi-Korhonen, L; Lassila, R; Pétas, A; Rannikko, AS; Säily, VM; Taari, K, 2014
)
0.4
" The rate of occurrences of adverse effects and bleeding were lower than those seen in the RE-LY trial."( A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation.
Hussin, A; Kaur, S; Muhammad, Z; Omar, R; Rusani, BI; Umadevan, D; Yap, LB, 2014
)
0.4
"Evaluate dabigatran adverse event reports with a reported bleeding event and/or reported fatal outcome compared with warfarin."( Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014
)
0.4
"Retrospective analysis of the FDA Adverse Event Reporting System (FAERS) database."( Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014
)
0.4
"Dabigatran was the primary suspected agent in 9029 adverse reports."( Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Bress, A; McConeghy, KW; Nutescu, EA; Qato, DM; Wing, C, 2014
)
0.4
" Beta-alanine intervention studies and review articles were collected from 13 databases, and safety information was collected from adverse event reporting portals."( Evidence-based evaluation of potential benefits and safety of beta-alanine supplementation for military personnel.
Cantilena, LR; Costello, RB; Deuster, P; Evans, WJ; Giancaspro, GI; Gorecki, DK; Hardy, ML; Jones, D; Jordan, SA; Ko, R; Low Dog, T; Maughan, RJ; Rankin, JW; Sarma, ND; Smith-Ryan, AE; Valerio, LG, 2014
)
1.55
" No adverse effects were noted for renal and hepatic clinical blood markers, resting heart rate, or BP."( Ingesting a preworkout supplement containing caffeine, creatine, β-alanine, amino acids, and B vitamins for 28 days is both safe and efficacious in recreationally active men.
Carson, LR; Esposito, EN; Fairman, CM; Falcone, PH; Joy, JM; Kendall, KL; Kim, MP; Moon, JR; Mosman, MM; Serrano, ER; Spradley, BD; Tai, CY, 2014
)
0.4
"Compared with warfarin, periprocedural anticoagulation with dabigatran resulted in fewer minor hemorrhages and total adverse events after AF ablation."( Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD, 2015
)
0.42
" Rywaroxaban more frequently causes minor bleeding, whereas treatment with dabigatran is associated with more frequent gastrointestinal adverse symptoms."( [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L, 2014
)
0.4
"Uninterrupted dabigatran therapy in CA for AF thus may be a safe and effective anticoagulant therapy, and appears to be closely similar to continuous warfarin; however, it is essential to pay close attention to the APTT values when using dabigatran during CA."( Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.
Fujita, M; Hirai, M; Inden, Y; Ishikawa, S; Kato, H; Miyoshi, A; Murohara, T; Nagao, T; Ohguchi, S; Okumura, S; Shimano, M; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015
)
0.42
" The most frequently reported adverse events (AEs) were ocular, with the most frequent ocular AE being conjunctival hyperemia, with an incidence of 61%, 66%, and 14%, respectively."( Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
Heah, T; Kahook, MY; Kim, T; Kopczynski, CC; Mah, FS; Novack, GD; Raizman, MB; Ramirez-Davis, N; Serle, JB; Usner, DW, 2019
)
0.51
"5%, with minimal treatment-related serious or systemic adverse events (AEs)."( Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
Fechtner, RD; Heah, T; Kim, T; Kopczynski, CC; Lewis, RA; McKee, H; Myers, JS; Sheng, H; Singh, IP; Usner, DW, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"Clinical pharmacokinetic studies in our laboratory demonstrated that 2-fluoro-beta-alanine (FBAL), the major catabolite of fluorouracil (FUra), has a prolonged elimination with an approximately 150-fold longer half-life than that of the unchanged drug in humans [Heggie et al."( Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil.
Barnes, S; Diasio, SB; Liu, TP; Soong, SJ; Zhang, RW,
)
0.61
"The pharmacokinetic behavior of panipenem (PAPM)-betamipron (BP), a new carbapenem, in humans was successfully predicted from data collected from six animal species."( Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data.
Hisaoka, M; Kawahara, Y; Kurihara, A; Naganuma, H; Tokiwa, H, 1992
)
0.28
" Pharmacokinetic studies."( [Pharmacokinetic, bacteriological, and clinical studies on panipenem/betamipron in children].
Abe, T; Fujii, R; Hata, M; Higa, A; Kondo, Y; Negishi, S; Nishimura, S; Tajima, T, 1992
)
0.28
" Pharmacokinetic analysis revealed a modest, but significant (up to 40%) elevation in the area under the plasma concentration-time curve during 6 h of the drug administration, and a reduction in L-734,217 plasma clearance and volumes of distribution, in the anesthetized dogs."( Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734,217, in dogs.
Cook, JJ; Ellis, JD; Hand, EL; Holahan, MA; Prueksaritanont, T; Sitko, GR; Stranieri, MT, 1997
)
0.3
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.55
" Systemic exposure based on plasma concentrations of capecitabine and its metabolites was determined using individual parameter estimates derived from a population pharmacokinetic model constructed for this purpose in NONMEM."( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003
)
0.32
" The primary pharmacokinetic parameter was AUC(0-infinity ) of 5'-deoxy-5-fluorouridine (5'-DFUR) on day 14."( Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Bridgewater, J; Grange, S; Kimura, M; Kuranami, M; Lucraft, H; McAleer, J; Monkhouse, J; Poole, C; Reigner, B; Saeki, T; Sasaki, Y; Schüller, J; Watanabe, T; Weidekamm, E; Yorulmaz, C, 2003
)
0.32
" Simulations were based on a population pharmacokinetic model derived from data from 9522 patients from the pivotal phase III study (RE-LY)."( Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012
)
0.38
" Based on its pharmacokinetic profile, dabigatran is dosed twice daily."( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012
)
0.38
"The pharmacokinetic profile of dabigatran was simulated for AF patients given a total daily dose of 300 mg, either once or twice daily."( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012
)
0.38
" Pharmacokinetic data collected from a phase II study and RE-LY were consistent with the simulation results."( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012
)
0.38
"To review the literature regarding the pharmacokinetic (PK) and clinical implications of the use of dabigatran in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation (AF)."( Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
Kim, JJ; Mack, DR,
)
0.13
" Though the anticoagulation efficacy of these NOACs has been characterized, differences in their pharmacokinetic and pharmacodynamic profiles have become a significant consideration in terms of drug selection and dosing."( Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Gong, IY; Kim, RB, 2013
)
0.39
" In this study, in vivo-based [I]/Ki values were used to predict the DDI risks of a P-gp substrate dabigatran etexilate (DABE) using physiologically based pharmacokinetic (PBPK) modelling."( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Hu, ZY; Zhao, Y, 2014
)
0.4
"This approach accurately predicted the effects of five P-gp inhibitors on DABE pharmacokinetics (98-133% and 89-104% for the ratios of AUC and Cmax respectively)."( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Hu, ZY; Zhao, Y, 2014
)
0.4
" POCT for aPTT is sensitive to increased concentrations of dabigatran, whereas the PT-POCT assessed with test systems such as the GEM PCL Plus may be helpful to measure the pharmacodynamic anticoagulant effects of rivaroxaban in emergency clinical situations."( Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Herrmann, E; Herth, N; Kasper, A; Lindhoff-Last, E; Linnemann, B; Mani, H; Pfeilschifter, W; Schuettfort, G; Weil, Y; Wendt, T, 2014
)
0.4
" The mean free dabigatran Cmax was 95."( An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis.
Anderson, DR; Goralski, KB; Morrison, M; Mossop, P; Sleno, L; Soroka, SD; Wang, Y; Wilson, JA, 2014
)
0.4
" Therefore, the previously identified increased toxicity and shorter survival in patients with a low SMM, could not be explained by changes in pharmacokinetic characteristics of capecitabine and metabolites."( Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Beijnen, JH; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Kurk, SA; May, AM; Molenaar-Kuijsten, L; Steeghs, N, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"Convulsant activity of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, in combination with nonsteroidal anti-inflammatory drug (NSAID) was investigated in mice after intravenous or intracerebroventricular administration."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
"We investigated the effect of beta-alanine (BA) alone (study A) and in combination with sodium bicarbonate (SB) (study B) on 100- and 200-m swimming performance."( The ergogenic effect of beta-alanine combined with sodium bicarbonate on high-intensity swimming performance.
Artioli, GG; Benatti, FB; Gualano, B; Harris, RC; Jesus, Fd; Lancha, AH; Painelli, Vde S; Roschel, H; Sale, C; Solis, MY, 2013
)
0.99
"In vitro inhibitory potency (Ki )-based predictions of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) are hampered by the substantial variability in inhibitory potency."( Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Hu, ZY; Zhao, Y, 2014
)
0.4
"To evaluate the effectiveness of netarsudil in combination with other ocular hypotensive agents in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)."( Effectiveness and Tolerability of Netarsudil in Combination with Other Ocular Hypotensive Agents.
Petito, LC; Pleet, AL; Prager, AJ; Tang, M; Tanna, AP,
)
0.13
"This study aimed to investigate the effect of multi-ingredient intra- (BA) versus extra- (ALK) cellular buffering factor supplementation, combined with the customary intake of branched-chain amino acids (BCAA) and creatine malate (TCM), on body composition, exercise variables, and biochemical and hematological parameters in 9 elite taekwondo athletes."( The effect of multi-ingredient intra- versus extra-cellular buffering supplementation combined with branched-chain amino acids and creatine on exercise-induced ammonia blood concentration and aerobic capacity in taekwondo athletes.
Durkalec-Michalski, K; Główka, N; Kusy, K; Zieliński, J, 2021
)
0.62
"In highly trained taekwondo athletes, neither extra- nor intracellular buffering enhancement resulting from BA and ALK supplementation, combined with BCAA and TCM treatment, affects body mass and composition, maximum oxygen uptake, and hematological indices, even though certain advantageous metabolic adaptations can be observed."( The effect of multi-ingredient intra- versus extra-cellular buffering supplementation combined with branched-chain amino acids and creatine on exercise-induced ammonia blood concentration and aerobic capacity in taekwondo athletes.
Durkalec-Michalski, K; Główka, N; Kusy, K; Zieliński, J, 2021
)
0.62
"Ultra-high-performance liquid chromatography-Q exactive orbitrap tandem mass spectrometry(UHPLC-QEOrbitrap-MS/MS) was used to explore the inhibitory effect and mechanism of ginkgo flavone aglycone(GA) combined with doxorubicin(DOX) on H22 cells."( [Cell metabolomics study of ginkgo flavone aglycone combined with doxorubicin against liver cancer in synergy].
Chen, JY; He, Y; Li, YJ; Liu, CH; Lu, Y; Song, ZJ; Wang, YL; Zhu, XQ, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
"50 mM baclofen solutions containing variable concentrations of the aminoacid (from 5 to 100 mM), a partially competitive inhibition of baclofen absorption was characterized: absorption rate pseudoconstants of the spasmolytic drug decrease as beta-alanine concentration increases, until a limiting value is obtained (36."( Partially competitive inhibition of intestinal baclofen absorption by beta-alanine, a nonessential dietary aminoacid.
Merino, M; Plá-Delfina, JM; Polache, A, 1991
)
0.7
" Similar results were obtained after oral dosing of the prodrugs, such that the bioavailability of L-767,679 was higher in dogs than in monkeys, and the bioavailability was higher after the ethyl ester than after the isopropyl prodrug in both species."( In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Baillie, TA; Breslin, MJ; Gorham, LM; Hartman, GD; Hutchinson, JH; Prueksaritanont, T; Vyas, KP, 1997
)
0.3
" In monkeys, the low input of L-767,679 following oral administration of the prodrug was not due to an inefficient formation of L-767,679 in the systemic circulation but rather to the low oral bioavailability of the prodrug."( Analysis of metabolite kinetics by deconvolution and in vivo-in vitro correlations of metabolite formation rates: studies of fibrinogen receptor antagonist ester prodrugs.
Gorham, LM; Prueksaritanont, T; Yeh, KC, 1997
)
0.3
" In addition, it would be highly advantageous if the bioavailability of these delivered agents could be monitored over time using non-invasive imaging techniques."( Crossing the blood-brain barrier: a potential application of myristoylated polyarginine for in vivo neuroimaging.
Lo, EH; Medarova, Z; Moore, A; Pham, W; Rosen, B; Zhao, BQ, 2005
)
0.33
" In animals, 10d showed moderate to good oral bioavailability and promoted food intake in tumor-bearing mice after oral administration."( Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.
Arellano, M; Chen, C; Chen, CW; Chen, T; Fleck, BA; Foster, AC; Hoare, SR; Jiang, W; Johns, M; Joppa, M; Madan, A; Marinkovic, D; Markison, S; Sai, Y; Saunders, J; Tran, JA; Tucci, F; Wen, J, 2007
)
0.34
" Germination of seeds for 5 days considerably improved the in vitro bioavailability of isolates, by 12%, and profile of sulfur amino acids by 42%, in comparison with isolates obtained from the raw seeds."( The effect of germination on antioxidant and nutritional parameters of protein isolates from grass pea (Lathyrus sativus) seeds.
Mickowska, B; Starzyńska-Janiszewska, A; Stodolak, B, 2010
)
0.36
" Possible mechanisms by which carnosine may perform its anti-tumourigenic effects are outlined and its expected bioavailability and possible negative and positive side effects are considered."( Carnosine and cancer: a perspective.
Gaunitz, F; Hipkiss, AR, 2012
)
0.38
" Ester 60 improved bioavailability of its parent ROCK inhibitor, 29 (Ki=0."( Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.
deLong, MA; Heintzelman, GR; Kopczynski, CC; Laethem, CL; Lin, CW; Moore, LA; Royalty, SM; Sherman, B; Sturdivant, JM; Yingling, JD, 2016
)
0.43

Dosage Studied

Dosing with carbon tetrachloride (CCl4) during treatment with beta-alanine results in a marked decrease in urinary taurine concomitant with a decrease in food intake. At the end of perfusion alpha-fluoro-beta-Alanine comprised 90 to 95% of FUDR-derived total radioactivity in the tissue. Potentiating Zn(2+) concentrations shifted the dose-response curves for the three agonists to the left.

ExcerptRelevanceReference
" The two current components have different dose-response characteristics, with the nondesensitizing component being activated more effectively at lower concentrations than the desensitizing component and also reaching its peak at lower concentrations."( A characterization of glycinergic receptors present in cultured rat medullary neurons.
Ahmed, Z; Faber, DS; Lewis, CA, 1991
)
0.28
" At the end of perfusion alpha-fluoro-beta-alanine comprised 90 to 95% of FUDR-derived total radioactivity in the tissue even at initially 2400 microM FUDR, although at this FUDR dosage 20% of the substrate remained unmetabolized in the medium."( Nonlinear elimination kinetics of 5-fluoro-2'-deoxyuridine in isolated perfused rat liver and isolated hepatocytes.
Foth, H; Kahl, GF; Kunellis, EM; Müseler, T, 1990
)
0.55
" By contrast, comparable oral dosing with BMAA precipitates tremor and weakness, bradykinesia and behavioural changes, with conduction deficits in the principal motor pathway."( Discovery and partial characterization of primate motor-system toxins.
Hugon, J; Ludolph, A; Nunn, PB; Ross, SM; Roy, DN; Schaumburg, HH; Spencer, PS, 1987
)
0.27
" Dosing with carbon tetrachloride (CCl4) during treatment with beta-alanine results in a marked decrease in urinary taurine concomitant with a decrease in food intake."( Reduction of liver taurine in rats by beta-alanine treatment increases carbon tetrachloride toxicity.
Scales, MD; Timbrell, JA; Turton, JA; Waterfield, CJ, 1993
)
0.8
" L-734,217 in dogs was unaffected by dosage form or food."( Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.
Cook, JJ; Drag, MD; Duggan, ME; Gehret, JR; Gould, RJ; Hand, EL; Hartman, GD; Holahan, MA; Ihle, NC; Kothstein, T; Lyle, EA; Lynch, JJ; McCormick, GY; Perkins, JJ; Ramjit, DR; Sitko, GR; Stranieri, MT; Stupienski, RF; Wallace, AA, 1996
)
0.29
" Similar results were obtained after oral dosing of the prodrugs, such that the bioavailability of L-767,679 was higher in dogs than in monkeys, and the bioavailability was higher after the ethyl ester than after the isopropyl prodrug in both species."( In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Baillie, TA; Breslin, MJ; Gorham, LM; Hartman, GD; Hutchinson, JH; Prueksaritanont, T; Vyas, KP, 1997
)
0.3
" The findings indicate that a method is available to rationally address the design of dosing schedules in concurrent therapy regimens."( Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Bachert, P; Becker, M; Dietz, A; Knopp, MV; Rudat, V; Schlemmer, HP; van Kaick, G; Vanselow, B; Wannenmacher, M; Weidauer, H; Wollensack, P; Zuna, I, 1999
)
0.3
" Our results suggest that postnatal alterations in the PAPM excretion are related to maturational changes in the renal function and that we should consider the values of PCA when determining the initial PAPM/BP dosing regimen in neonates."( [Pharmacokinetics of panipenem in neonates and dosage recommendation].
Kimura, T; Kokubun, H; Matsuura, N; Nishisako, M; Nonoyama, M; Nowatari, M; Oguchi, K; Shimada, S; Sunakawa, K, 2000
)
0.31
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.55
" In addition, concurrent dosing of BPAA (1 microgram/body) did not reduce the convulsion-inducing dose of PZFX mesilate."( [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
Fukuda, H; Kawamura, Y, 2002
)
0.31
" The present results have no clinical implications for the use of capecitabine and argue against the value of therapeutic drug monitoring for dosage adjustment."( Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003
)
0.32
" Potentiating Zn(2+) concentrations shifted the dose-response curves for the three agonists to the left and decreased the Hill coefficient for glycine and beta-alanine but not taurine."( Modulation of inhibitory glycine receptors in cultured embryonic mouse hippocampal neurons by zinc, thiol containing redox agents and carnosine.
Thio, LL; Zhang, HX, 2006
)
0.53
" In the first step, amino acids are continuously dosed from an infinite volume reservoir by electromigration to the column, where a sharp, stationary neutralization reaction boundary (NRB) is created in between acidic and basic primary electrolyte."( Analysis of amino acids by combination of carrier ampholyte-free IEF with ITP.
Glovinová, E; Pospíchal, J; Procházková, B, 2007
)
0.34
"We introduce a system for temperature control of a commercial microfluidic superfusion device that, in combination with patch-clamp, enables rapid acquisition of dose-response data at different temperatures."( Ligand-specific temperature-dependent shifts in EC50 values for the GABAA receptor.
Bridle, H; Jesorka, A; Lincoln, P; Millingen, M; Orwar, O, 2008
)
0.35
" In mass balance studies using [(14)C]-ICAM1988 in rats dosed intravenously, unchanged ICAM1988 contributed to 25."( Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug.
Baumgardner, MJ; Bloedow, DC; Bodary, SC; Desino, KE; Gadek, TR; Gudmundsson, OS; Kenkare-Mitra, S; Khojasteh, SC; La, H; Lai, F; Leipold, DD; Reynolds, ME, 2008
)
0.35
" A recent provocative report indicated that low dosage of the sphingosine analog FTY720 caused lymphopenia in mice persistently infected with lymphocytic choriomeningitis virus (LCMV)-clone 13 (Cl 13) and induced viral clearance within 30 days post-treatment (Premenko-Lanier et al."( Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.
Marsolais, D; Oldstone, MB; Rosen, H; Walsh, KB; Welch, MJ, 2010
)
0.36
" They can be prevented by using controlled release capsules and smaller dosing strategies."( Role of beta-alanine supplementation on muscle carnosine and exercise performance.
Artioli, GG; Gualano, B; Lancha, AH; Smith, A; Stout, J, 2010
)
0.79
" Four isomeric acylglucuronides of dabigatran were isolated and purified from urine of dosed rhesus monkeys."( Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity.
Ebner, T; Wagner, K; Wienen, W, 2010
)
0.36
" The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients."( Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Baker, WL; Bendel, SD; Bona, R, 2011
)
0.37
" Additional concerns refer to the dosing-regimens and their practical administration: Fondaparinux, rivaroxaban and dabigatran are dosed to achieve maximum effects very close to their limits of tolerance whereas wide dosing spectra for the low molecular weight herparin (LMWH)'s indicate the potential for dose adaptation and increase."( Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Fareed, J; Hull, R; Welzel, D, 2011
)
0.37
" This placebo-controlled, double-blind study compared two different 8-week BA dosing regimens on the time course of muscle carnosine loading and 8-week washout, leading to a BA dose-response study with serial muscle carnosine assessments throughout."( Effect of two β-alanine dosing protocols on muscle carnosine synthesis and washout.
Anwander, H; Boesch, C; Buehler, T; Decombaz, J; Egger, A; Kreis, R; Stellingwerff, T, 2012
)
0.38
" Clinicians are increasingly being challenged with making uncertain anticoagulant dosing decisions, as the optimal dosing strategy for most anticoagulants in the obese patient population remains unknown."( Anticoagulating obese patients in the modern era.
Arya, R; Patel, JP; Roberts, LN, 2011
)
0.37
" The aim of this analysis was to derive a modeling and simulation-based dose and dosing regimen for AF patients with severe renal failure who could potentially benefit from the use of DE."( Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Clemens, A; Friedman, J; Haertter, S; Lehr, T; Liesenfeld, KH; Reilly, PA; Staab, A, 2012
)
0.38
"The objective of this work was to derive a dosing regimen for dabigatran in patients with severe renal impairment by modeling and simulation."( Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
Hariharan, S; Madabushi, R, 2012
)
0.38
" The dosage of 110 mg bid should be preferably used in patients older than 75 years at a higher bleeding risk."( Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012
)
0.38
" Because dabigatran is cleared principally by the kidneys, dosage adjustments are required in the setting of renal dysfunction."( Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
Augoustides, JG, 2011
)
0.37
" This preliminary evidence, while intriguing, requires confirmation in post-stroke patients receiving orally dosed D in order to determine whether these findings are clinically relevant."( Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.
Fong, A; Hanley, D; Lynch, D; Sani, Y; Schevchuck, A; Serebruany, V; Svetlov, S; Thevathasan, L, 2012
)
0.38
" Heparin was not used postoperatively and transition dosing from dabigatran to warfarin was started on postoperative day 8, the day of discharge."( Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
Fieland, D; Taylor, M, 2012
)
0.38
" Based on its pharmacokinetic profile, dabigatran is dosed twice daily."( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012
)
0.38
" For patients who miss or delay taking one scheduled dabigatran dose, twice daily dosing maintained adequate minimum trough concentrations better than once daily dosing."( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012
)
0.38
" The efficacy and safety of this dosing regimen is supported by clinical data from the RE-LY trial."( Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Brueckmann, M; Clemens, A; Friedman, J; Haertter, S; Lehr, T; Stangier, J; van Ryn, J, 2012
)
0.38
" Supporting this, a recent dose-response study demonstrated a large linear dependency (R2=0."( Optimizing human in vivo dosing and delivery of β-alanine supplements for muscle carnosine synthesis.
Boesch, C; Decombaz, J; Harris, RC; Stellingwerff, T, 2012
)
0.38
" The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option."( Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Halperin, JL; Varughese, CJ, 2012
)
0.38
" Dosed twice daily, dabigatran offers recipients the ability to forego regular international normalized ratio coagulation monitoring as well as eliminating dietary restrictions (i."( Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Freeman, MK; Hughes, PJ, 2012
)
0.38
" These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin."( Newer oral anticoagulant agents: a new era in medicine.
Goel, R; Srivathsan, K, 2012
)
0.38
" The dosage of 110 mg BID should be preferably used in patients aged 75-80 years or older as the rate of extracranial bleeding events tends to increase with dabigatran 150 mg BID above this age limit."( Dabigatran for stroke prevention in atrial fibrillation.
Diener, HC; Hohnloser, SH, 2012
)
0.38
" Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost-effectiveness of dabigatran compared with warfain."( Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
Cheng, G; Tsui, KK; Wong, RS; You, JH, 2012
)
0.38
" The approved dosing regimen for patients with creatinine clearance 15-30 mL/min (75 mg twice daily) was derived from PK modeling studies, limiting its applicability to the clinical setting."( Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
Kim, JJ; Mack, DR,
)
0.13
" This review will provide an overview of the physiology that underlies the mechanisms of action behind β-alanine, examine dosing schemes, and examine the studies that have been conducted on the efficacy of this supplement."( β-Alanine supplementation.
Emerson, NS; Hoffman, JR; Stout, JR,
)
0.13
" It is suggested to perform EXCA tests for each individual patient to determine the real drug dosage he needs to reach 10-20% of normal EXCA for therapy or 20-40% of normal EXCA for prophylaxis."( Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
Stief, TW, 2012
)
0.38
" The requirement for a twice-daily dosage regimen, the lack of an anticoagulation monitoring option, the relatively short duration of action and the lack of an antidote may even prove to be crucial disadvantages in clinical practice in comparison to vitamin K antagonists."( [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Berthold, HK, 2012
)
0.38
" These data suggest that direct thrombin inhibition in a relevant dosage improved endothelial function and reduced atherosclerotic lesion size, collagen content, and oxidative stress in hypercholesterolemic atherosclerosis."( The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.
Baumhäkel, M; Böhm, M; Kratz, MT; Lee, IO; Schirmer, SH, 2012
)
0.38
" Much of the literature associated with dabigatran encourages this view, stressing that dabigatran is a 'game changer' with the advantage of fixed dosing for most patients and no anticoagulation monitoring."( Dabigatran: rational dose individualisation and monitoring guidance is needed.
Al-Sallami, HS; Duffull, SB; Faed, JM; Wright, DF; Zufferey, PJ, 2012
)
0.38
" Patients who met at least one caution or contraindication criteria were deemed "non-candidates"; potential dosage reductions of the new oral anticoagulants were not considered."( Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.
Carter, KL; Kraus, PS; Ross, PA; Shermock, KM; Streiff, MB; Thomas, ML; Wellman, JC, 2012
)
0.38
" Based on the RE-LY and ROCKET AF trial results, we investigated the cost-effectiveness of dabigatran (twice daily dosing of 150 mg or 110 mg based on patient age) versus rivaroxaban from a Canadian payer perspective."( Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV, 2012
)
0.38
" Linearity of dose-response and responsiveness to increasing dose in addition to standardization are other important issues to consider."( Laboratory tests and the new oral anticoagulants.
Tripodi, A, 2012
)
0.38
" The first, monitoring, implies laboratory testing to assess the drug's effect and to adjust the dosage to maintain anticoagulation within the therapeutic interval."( The laboratory and the new oral anticoagulants.
Tripodi, A, 2013
)
0.39
" The choice of tests is based on such characteristics as availability, linearity of the dose-response curve, standardization, and responsiveness to increasing drug dosage."( The laboratory and the new oral anticoagulants.
Tripodi, A, 2013
)
0.39
" Nineteen percent reported some difficulty with twice daily dosing adherence with 13 of 70 reporting missed doses."( Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.
Boga, T; Michel, J; Mundell, D; Sasse, A, 2013
)
0.39
" In several murine models of diabetes, acute and chronic dosing with GRA1 significantly reduced blood glucose concentrations and moderately increased plasma glucagon and glucagon-like peptide-1."( Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist.
Brady, EJ; Candelore, MR; Dallas-Yang, Q; Jiang, G; Langdon, RB; Li, Z; Miller, C; Mu, J; Muise, ES; Parmee, ER; Qureshi, SA; Wu, MS; Xiong, Y; Yang, X; Zhang, BB, 2012
)
0.38
" A sequential dosage scheme, in which 150 mg are administered up to the age of 80 years and 110 mg thereafter, resulted in an ICER of CHF 10,215 per QALY."( Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland.
Eichler, K; Plessow, R; Pletscher, M; Wieser, S, 2013
)
0.39
" In an open-label, single-centre phase I study with two fixed multiple dosing periods, we investigated the pharmacokinetics, pharmacodynamics and safety of dabigatran before, during and after 4 hour haemodialysis sessions with either 200 or 400 ml/min targeted blood flow in seven end-stage renal disease patients without atrial fibrillation."( Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
Clemens, A; Formella, S; Friedman, J; Härtter, S; Khadzhynov, D; Lehr, T; Liesenfeld, KH; Moschetti, V; Neumayer, HH; Peters, H; Slowinski, T; Wagner, F; Wiegert, E, 2013
)
0.39
" Because it appears that this has not been previously described for β2-agonists and because pharmacodynamic/pharmacokinetic factors may influence the response, studies using repeated dosing were performed to investigate whether this would lead to compound-induced tachyphylaxis with tolerance induction and decreased responses indicated by β2-effect biomarkers."( Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. II: long-acting beta-2 agonism.
Åberg, P; Fred, C; Mutch, P; Nicholls, DJ; O'Donovan, MR; Pohl, CD; Pontén, I; Saad, A; Young, A, 2013
)
0.39
" Rivaroxaban, apixaban, and dabigatran have different pharmacological characteristics, and guidance is needed on optimum doses and dosing intervals and the effects of renal or hepatic impairment, age, food, and other drugs."( Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.
Graff, J; Harder, S, 2013
)
0.39
" Dabigatran was granted marketing authorisation by the European Medicines Agency for a sequential dosing regimen (DBG sequential), in which patients under 80 years are treated with dabigatran 150 mg twice daily (DBG150) and patients 80 years and over are given dabigatran 110 mg twice daily (DBG110)."( Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.
Burch, J; Corbacho, B; Faria, R; Palmer, S; Pepper, C; Spackman, E; Todd, D; Woolacott, N, 2013
)
0.39
" Consequently, if renal function is impaired, there is a risk of drug accumulation that is highest for dabigatran followed by rivaroxaban and then apixaban and thus dosing recommendations are different."( Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R, 2013
)
0.39
" In this review, we outline key pharmacokinetic and pharmacodynamic features of each compound and provide guidance on selection and dosing of the 3 NOACs relative to warfarin when considering OAC therapy for AF patients."( Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Gong, IY; Kim, RB, 2013
)
0.39
" Much remains to be learned about the optimal use of the novel oral anticoagulants in CKD patients; additional studies about optimal dosing of the novel oral anticoagulants and frequency of monitoring renal function in CKD patients with atrial fibrillation are needed."( Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Brimble, KS; Eikelboom, JW; Hart, RG; Ingram, AJ; McMurtry, MS, 2013
)
0.39
" If the anticoagulant dosage is not immediately available, worse propositions, based on the usual tests (prothrombin time and activated partial thromboplastin time), are presented."( Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S,
)
0.13
" However the choice of dosing regimens in different clinical conditions has been different for the various NOACs, and has been established on the basis of widely different considerations, including the clinical setting (venous versus arterial thrombosis), the indications (prophylaxis versus treatment), the likelihood of concomitant antiplatelet drugs, and marketing opportunities; these latter were based on the knowledge that patients' compliance is generally better with once daily than with twice daily dosing."( The new oral anticoagulants in atrial fibrillation: once daily or twice daily?
De Caterina, R; Renda, G,
)
0.13
" These new anticoagulants do not require strict and frequent laboratory monitoring, dosing adjustments, or dietary restrictions, and they incur fewer drug-drug interactions than warfarin."( Novel oral anticoagulants: a review of new agents.
Wanat, MA, 2013
)
0.39
" If the dosage of the drug is not immediately available, proposals only based on the usual tests, PT and aPTT, also are presented."( [Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S, 2013
)
0.39
" The authors recommend caution while dosing dabigatran in the Asian population, as the estimates of kidney functioning vary substantially depending on the formula used to estimate GFR, which may in turn lead in some cases of inadequate dosing of dabigatran."( A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Azuma, S; Lum, CJ, 2013
)
0.39
"Pharmacogenetics-guided warfarin dosing is an alternative to standard clinical algorithms and new oral anticoagulants for patients with nonvalvular atrial fibrillation."( Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Hughes, DA; Lane, S; Pink, J; Pirmohamed, M, 2014
)
0.4
" Adjusted dosage of dabigatran to 110 mg/bid according to renal clearance in combination with 150 mg/day aspirin was started."( [Severe thrombosis of bioprosthesis mitral valve after dabigatran].
Akgüllü, C; Eryılmaz, U; Kurtoğlu, T, 2013
)
0.39
" Advantages and disadvantages to using these newer agents are presented, as are dosing adjustments for renal and hepatic impairment."( Outpatient management of oral anticoagulation in atrial fibrillation.
Manning, JA, 2013
)
0.39
" These data suggest cautious early uptake of dabigatran, and more careful attention to dosing adjustments is warranted."( Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.
Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Holmes, DN; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013
)
0.39
" These drugs differ in a several important respects from warfarin; most notably they have a reliable dose-response effect which means they can be given without the need for monitoring."( New oral anticoagulants: their role and future.
Laffan, M; Shapiro, S, 2013
)
0.39
" The objective of the study was to validate a dosing regimen for use of dabigatran in patients with mechanical heart valves."( Dabigatran use in mechanical heart valve patients.
Pai, RG; Tafreshi, J; Zough, F, 2014
)
0.4
" In contrast to warfarin, most NOACs need dosage adjustments in renal impairment and are contraindicated in severe liver impairment, and there are no specific antidotes for treating NOAC-related over-anticoagulation."( New oral anticoagulants in practice: pharmacological and practical considerations.
Bajorek, B; Wang, Y, 2014
)
0.4
" The HTI dosage could help managing the treatment in case of severe bleeding event."( Impaired renal function and bleeding in elderly treated with dabigatran.
Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L, 2014
)
0.4
" They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring."( Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014
)
0.4
" However, in elderly patients with impaired renal function or considerable bleeding risks, label advice regarding dosing needs strict observation."( Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.
Harder, S; Meyer Dos Santos, S, 2014
)
0.4
"Clinical results of the European Action on Anticoagulation (EAA) computer-assisted dosage study and the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial have been compared."( Warfarin or dabigatran for treatment of atrial fibrillation.
Ibrahim, S; Jespersen, J; Poller, L, 2014
)
0.4
" Other reasons included dosing frequency (5."( Continuation of dabigatran therapy in "real-world" practice in Hong Kong.
Chan, EW; Chan, KH; Chan, PH; Cheung, E; Hai, JJ; Ho, CW; Ho, MH; Leung, GK; Siu, CW; Tse, HF, 2014
)
0.4
"Compared to Vitamin K antagonists (VKA), novel oral anticoagulants (NOACs) appear to be safer in terms of major bleeding risks with added advantage of having fixed dosing schedules when used in patients with non-valvular atrial fibrillation (AF)."( Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J, 2015
)
0.42
"Ease of dosing and simplicity of monitoring make new oral anticoagulants an attractive therapy in a growing range of clinical conditions."( Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
Baumann Kreuziger, LM; Dries, DJ; Keenan, JC; Morton, CT, 2014
)
0.4
" Coagulation biomarkers in shed blood were assessed at 3 h after monotherapy with the medicines under study, at 3 h after triple therapy dosing and at steady state trough conditions."( Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M, 2014
)
0.4
" Practical advantages of NOACs over warfarin include fixed once- or twice-daily oral dosing without the need for coagulation monitoring, and few known or defined drug or food interactions."( Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Bell, AD; Douketis, J; Eikelboom, J; Liew, A, 2014
)
0.4
" It has also been used in patients for other indications as a substitute for warfarin therapy because it requires no monitoring; one group being patients undergoing radiofrequency (RF), ablation for AF, although there have been no consensus guidelines with regards to dosage and timing of dose."( Left atrial appendage thrombus with resulting stroke post-RF ablation for atrial fibrillation in a patient on dabigatran.
Hussaini, A; Kiernan, TJ; Lobo, R; McCann, C; Meany, TB,
)
0.13
" Moreover, it also has attempted to establish a specific dosage that maximizing the potential benefits, minimize paresthesia, the main side effect presented in response to supplementation."( [Effects of ß-alanine supplementation on athletic performance].
Domínguez, R; Garnacho-Castaño, MV; Hernández Lougedo, J; Maté-Muñoz, JL, 2014
)
0.4
" Animals were dosed with AR-13324 (0."( Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits.
Kiel, JW; Kopczynski, CC, 2015
)
0.42
" The RapidTEG activated clotting time test allowed the creation of a dose-response curve for all 3 NOACs."( Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL, 2015
)
0.42
" The increased incidence of major bleeding (excluding fatal) due to fondaparinux could be perhaps lowered by dosage reduction in patients with a mildly decreased creatinine clearance."( [Contribution of novel anticoagulants fondaparinux and dabigatran to venous thromboembolism prevention].
Antonijević, N; Apostolović, M; Jovanović, L; Kanjuh, V; Vukčević, M; Živković, I,
)
0.13
" The mean dosage of dabigatran was 211."( Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition.
Fujino, T; Ikeda, T; Kabuki, T; Kiuchi, S; Kobayashi, K; Yamazaki, A; Yamazaki, J; Yamazaki, Y, 2015
)
0.42
"To conduct a dose-response assessment of the efficacy and safety of the glucagon receptor antagonist PF-06291874 in adults with type 2 diabetes (T2DM) using stable doses of metformin."( Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.
Bergman, AJ; Calle, RA; Chidsey, K; Kazierad, DJ; Somayaji, VR, 2018
)
0.48
" This study therefore investigated the effect of two βA dosing strategies on 30-min rowing and subsequent sprint performance."( The effect of two β-alanine dosing strategies on 30-minute rowing performance: a randomized, controlled trial.
Antonio, J; Beasley, L; Gordon, D; Johnstone, J; Roberts, J; Smith, L, 2018
)
0.48
" In an acute dog glucagon challenge test, compound 13K significantly inhibited glucagon-mediated blood glucose increase when dosed orally at 10 mg/kg."( Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.
Demarest, K; DesJarlais, RL; DiLoreto, K; Du, F; Eckardt, A; Gaul, MD; Liang, Y; Rentzeperis, D; Santulli, R; Shook, B; Song, F; Xu, G, 2019
)
0.51
"Personalised dosing of performance-enhancing food supplements is a hot topic."( Fragmented Dosing of β-alanine Induces A Body Weight-Independent Pharmacokinetic Response.
Derave, W; Pringels, L; Stautemas, J; Van de Loock, A; Van der Stede, T, 2019
)
0.51
"Intraocular pressure curves were acquired over a 3-day acclimation period, 5-day dosing period (QD or BID-10 dogs/group), and 3-day recovery period."( Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.
Keys, DA; La Croix, NC; Miller, PE; Yang, VY, 2021
)
0.62
"02% showed no clinically significant effects on ECD, CV, or %HEX when dosed QD or BID for 3 months in eyes with OHTN or OAG."( Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial.
Heah, T; Mah, F; Mundorf, T; Sheng, H,
)
0.13
"04% dosed QD (P."( Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
Araie, M; Aso, K; Hollander, DA; Kanemoto, K; Kopczynski, C; Kothapalli, K; Senchyna, M; Sugiyama, K, 2021
)
0.62
" Enhanced supply of another precursor, β-alanine was achieved by codon optimization and dosing of the limiting L-asparate-1-decarboxylase (ADC)."( Engineering precursor and co-factor supply to enhance D-pantothenic acid production in Bacillus megaterium.
Allampalli, SSP; Nehru, G; Sivaprakasam, S; Tadi, SRR, 2022
)
0.72
" Studies of caffeine in women suggest the physiological responder status and caffeine habituation may contribute to caffeine's efficacy, with a potential plateau in the dose-response relationship of performance enhancement."( Dietary Supplements for Athletic Performance in Women: Beta-Alanine, Caffeine, and Nitrate.
Hackney, AC; Murphy, MJ; Rushing, BR; Sumner, SJ, 2022
)
0.97
" By reviewing these supplements' mechanisms, evidence relating directly to improving sports performance, and ideal dosing strategies, we provide a reference for athletes and medical staff to personalize supplementation strategies."( The Impact of Supplements on Sports Performance for the Trained Athlete: A Critical Analysis.
Fredericson, M; Kaufman, MW; Roche, M, 2022
)
0.72
"This meta-analysis study suggests that beta-alanine supplementation is unlikely to improve body composition indices regardless of supplementation dosage and its combination with exercise training."( Effects of beta-alanine supplementation on body composition: a GRADE-assessed systematic review and meta-analysis.
Asbaghi, O; Ashtary-Larky, D; Bagheri, R; Ghanavati, M; Stout, JR; Suzuki, K; Wong, A, 2022
)
1.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (19 Items)

ItemProcessFrequency
Beveragescore-ingredient6
Compléments alimentairescore-ingredient4
Protein powderscore-ingredient4
Bodybuilding supplementscore-ingredient4
Dietary supplementscore-ingredient4
Compléments pour le Bodybuildingcore-ingredient3
Protéines en poudrecore-ingredient2
Energy drinkscore-ingredient2
Sodascore-ingredient1
Carbonated drinkscore-ingredient1
en:Creatinecore-ingredient1
Suplementos dietéticoscore-ingredient1
Energy Drinkcore-ingredient1
Artificially sweetened beveragescore-ingredient1
en:dietary-supplementscore-ingredient1
fr:Pre-workoutcore-ingredient1
Vitamin mineral combinationscore-ingredient1
en:bodybuilding-supplementscore-ingredient1
Energy drink without sugar and with artificial sweetenerscore-ingredient1

Roles (5)

RoleDescription
neurotransmitterAn endogenous compound that is used to transmit information across the synapse between a neuron and another cell.
inhibitorA substance that diminishes the rate of a chemical reaction.
agonistSubstance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
beta-amino acidA non-proteinogenic amino acid in which the amino group is located on the carbon atom at the position beta to the carboxy group.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (29)

PathwayProteinsCompounds
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Histidine Metabolism1735
Pyrimidine Metabolism2353
Aspartate Metabolism1430
beta-Alanine Metabolism927
Propanoate Metabolism1837
Canavan Disease1430
Hypoacetylaspartia1430
GABA-Transaminase Deficiency927
Histidinemia1735
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Malonic Aciduria1837
Methylmalonic Aciduria Due to Cobalamin-Related Disorders1837
Ureidopropionase Deficiency927
Carnosinuria, Carnosinemia927
Malonyl-CoA Decarboxylase Deficiency1837
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
2-Oxo-glutaric acid + beta-Alanine = L-Glutamic acid + Malonate semialdehyde ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Histidine degradation ( Histidine degradation )2326
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Leucine, isoleucine and valine metabolism2470
Carnosine metabolism of glial cells09
AtMetExpress overview0109
Alanine and aspartate metabolism015
Biochemical pathways: part I0466
Pyrimidine metabolism038
GABA metabolism (aka GHB)1128

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency2.99350.531815.435837.6858AID504845
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)2,818.37990.00011.753610.0000AID759056
Sodium- and chloride-dependent GABA transporter 1Mus musculus (house mouse)IC50 (µMol)2,779.99660.03712.19228.5114AID1736174; AID595473; AID759056
Sodium- and chloride-dependent GABA transporter 2Mus musculus (house mouse)IC50 (µMol)378.88951.41255.26838.1283AID1736175; AID1736176; AID595474; AID759053
Sodium- and chloride-dependent GABA transporter 3Mus musculus (house mouse)IC50 (µMol)55.39981.54883.67618.1283AID1736177; AID595475; AID759054
Sodium- and chloride-dependent betaine transporterMus musculus (house mouse)IC50 (µMol)331.13100.18003.188010.0000AID759055
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)11.60000.00071.600310.0000AID143615
Sodium- and chloride-dependent GABA transporter 3Homo sapiens (human)IC50 (µMol)41.20001.00004.13318.9200AID1188932; AID764976
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)11.60000.00071.630610.0000AID143615
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)11.60000.00061.525710.0000AID143615
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)11.60000.00071.747210.0000AID143615
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)11.60000.00071.741110.0000AID143615
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)11.60000.00071.741110.0000AID143615
Sodium- and chloride-dependent GABA transporter 2Homo sapiens (human)IC50 (µMol)154.50006.20006.20006.2000AID1188931; AID764977
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)11.60000.00071.741110.0000AID143615
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (38)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
amino acid transmembrane transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
response to xenobiotic stimulusSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
monocarboxylic acid transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
taurine transmembrane transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
gamma-aminobutyric acid reuptakeSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
amino acid transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
nitrogen compound transportSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
monocarboxylic acid transportSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
taurine transmembrane transportSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
creatine transmembrane transportSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
gamma-aminobutyric acid reuptakeSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
gamma-aminobutyric acid importSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
nitrogen compound transportSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
amino acid import across plasma membraneSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
transport across blood-brain barrierSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
amino acid transportSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
gamma-aminobutyric acid:sodium:chloride symporter activitySodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
taurine:sodium symporter activitySodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
monocarboxylic acid transmembrane transporter activitySodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
amino acid bindingSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid:sodium symporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
creatine transmembrane transporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
gamma-aminobutyric acid:sodium:chloride symporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
taurine transmembrane transporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
taurine:sodium symporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
monocarboxylic acid transmembrane transporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
amino acid transmembrane transporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
gamma-aminobutyric acid transmembrane transporter activitySodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
presynaptic membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
postsynaptic membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
GABA-ergic synapseSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
plasma membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
cell projectionSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
basolateral plasma membraneSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
extracellular exosomeSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
presynapseSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
plasma membraneSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
cell projectionSodium- and chloride-dependent GABA transporter 2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID255583Percent inhibition of CD40 expression in BCL1 cells treated with 10 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID198302Cleavage rate against hairpin ribozyme at 5 mM with 0.5 uM magnesium ions2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Novel spermine-amino acid conjugates and basic tripeptides enhance cleavage of the hairpin ribozyme at low magnesium ion concentration.
AID1188931Inhibition of human GAT2 transfected in CHO cells assessed as [3H]GABA uptake after 20 mins by liquid scintillation counting analysis2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor.
AID595474Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1188932Inhibition of human GAT3 transfected in CHO cells assessed as [3H]GABA uptake after 20 mins by liquid scintillation counting analysis2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor.
AID759053Inhibition of GABA uptake at murine GAT-2 expressed in HEK293 cells2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis of N-substituted acyclic β-amino acids and their investigation as GABA uptake inhibitors.
AID759054Inhibition of GABA uptake at murine GAT-3 expressed in HEK293 cells2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis of N-substituted acyclic β-amino acids and their investigation as GABA uptake inhibitors.
AID603205Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as alpha-helix structural changes by crystal structure analysis (Rvb = 41.3 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID759056Inhibition of GABA uptake at murine GAT-1 expressed in HEK293 cells2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis of N-substituted acyclic β-amino acids and their investigation as GABA uptake inhibitors.
AID603206Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as beta-sheet structural changes by crystal structure analysis (Rvb = 21.3 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID255581Percent inhibition of CD40 expression in BCL1 cells treated with 3 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID1736176Inhibition of mouse GTA 3 receptor2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID143615Inhibitory concentration required to inhibit [3H]strychnine binding to N-methyl-D-aspartate glutamate receptor 1 of rat spinal cord membranes.1992Journal of medicinal chemistry, Jan-24, Volume: 35, Issue:2
Beta-proline analogues as agonists at the strychnine-sensitive glycine receptor.
AID595475Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1736174Inhibition of mouse GTA 1 receptor2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID595476Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID603203Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as alpha-helix structural changes by circular dichroism spectra analysis (Rvb = 47.93 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID255579Percent inhibition of CD40 expression in BCL1 cells treated with 1 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID764977Inhibition of human GAT2 transfected in CHO cells assessed as [3H]GABA uptake after 20 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports.
AID759055Inhibition of GABA uptake at murine BGT-1 expressed in HEK293 cells2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis of N-substituted acyclic β-amino acids and their investigation as GABA uptake inhibitors.
AID603204Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as beta-sheet structural changes by circular dichroism spectra analysis (Rvb = 8.19 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID681145TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Genomics, Jan, Volume: 79, Issue:1
The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location.
AID764976Inhibition of human GAT3 transfected in CHO cells assessed as [3H]GABA uptake after 20 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports.
AID51035Concentration required for obtaining 50% of the fluorescence intensity of copper-free calcein 1, in bovine serum albumin at 10 mM concentration2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
A green fluorescent chemosensor for amino acids provides a versatile high-throughput screening (HTS) assay for proteases.
AID198301Cleavage rate against hairpin ribozyme at 2 mM, in presence of 0.5 uM magnesium ions2001Bioorganic & medicinal chemistry letters, Dec-03, Volume: 11, Issue:23
Novel spermine-amino acid conjugates and basic tripeptides enhance cleavage of the hairpin ribozyme at low magnesium ion concentration.
AID1736177Inhibition of mouse GTA4 receptor2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID595473Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1736175Inhibition of mouse GTA 2 receptor2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID603208Binding affinity to Mycobacterium tuberculosis pantothenate synthetase by tryptophan fluorescence quenching assay2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID1345380Human MRGPRD (Class A Orphans)2004The Journal of biological chemistry, May-28, Volume: 279, Issue:22
Identification of a G protein-coupled receptor specifically responsive to beta-alanine.
AID1345380Human MRGPRD (Class A Orphans)2013Journal of biomolecular screening, Jun, Volume: 18, Issue:5
Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.
AID1345376Rat MRGPRD (Class A Orphans)2004The Journal of biological chemistry, May-28, Volume: 279, Issue:22
Identification of a G protein-coupled receptor specifically responsive to beta-alanine.
AID1345371Mouse MRGPRD (Class A Orphans)2004The Journal of biological chemistry, May-28, Volume: 279, Issue:22
Identification of a G protein-coupled receptor specifically responsive to beta-alanine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,073)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990354 (11.52)18.7374
1990's392 (12.76)18.2507
2000's451 (14.68)29.6817
2010's1656 (53.89)24.3611
2020's220 (7.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.71 (24.57)
Research Supply Index8.13 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index196.31 (26.88)
Search Engine Supply Index3.97 (0.95)

This Compound (56.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials207 (6.52%)5.53%
Reviews458 (14.42%)6.00%
Case Studies220 (6.92%)4.05%
Observational15 (0.47%)0.25%
Other2,277 (71.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]